Alkem Laboratories Ltd (ALKEM) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- Alkem Laboratories reported a landmark year, surpassing 3,000 crores in annual EBITDA, driven by strong, broad-based growth across both domestic and international markets.
- The company demonstrated robust performance with a 14.6% YoY revenue growth in Q4, supported by healthy momentum in the India branded generics business and a significant 25.4% YoY growth in international sales.
- A key highlight was the successful day-one launch of Semaglutide (a GLP-1 agonist) in March 2026, which quickly garnered an 11% unit market share, signaling strong initial traction and a significant future growth driver for the chronic portfolio.
- The company achieved meaningful margin expansion during the year, attributed to an improving business mix, operational leverage, and disciplined cost management, resulting in a Q4 EBITDA margin of 14.4%.
- Management remains optimistic about sustaining momentum in FY27, focusing on execution, portfolio mix improvement, and expanding its differentiated pipeline, despite acknowledging near-term headwinds from geopolitical tensions affecting logistics and raw material costs.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.